Global In-vitro Diagnostics Market to Surpass US$ 903.3 Billion by 2026
According to Coherent Market Insights, the global in-vitro diagnostics market was valued at US$ 60,274.1 million in 2017, and is projected to exhibit a CAGR of 4.6% over the forecast period (2018?2026).
Key Trends and Analysis of the Global In-vitro Diagnostics Market:
Key trends in market are rising prevalence of cancer and autoimmune diseases, extensive merger and acquisition activities, and rising trend of point-of-care testing by key players.
Increasing prevalence of cancer and autoimmune diseases is expected to augment the market growth. Incidence rate of autoimmune diseases varies according to ethnicity and region. According to American Autoimmune Related Disease Association (AARDA), in 2016, around 50 million people suffered from autoimmune diseases in the U.S. with 75% being women. Similarly, according to the National Cancer Institute 2016, an estimated 1,685,210 new cancer cases will be diagnosed in the U.S. with an approximate 595,690 people expected to die from the disease.
Increasing product launch by market players is expected to contribute to growth of global in-vitro diagnostics market over the forecast period. For instance, in 2016, F. Hoffmann-La Roche Ltd, launched CT/NG on the cobas 6800/8800 Systems in markets accepting the CE mark. It is the first CE-IVD cleared molecular test for CT/NG to receive claims for testing anorectal and oropharyngeal samples, offering a broader access to high risk patient population.
Furthermore, key players operating in the market are focused on adopting acquisition and collaboration strategies, in order to expand their product offerings in markets. For instance, in September 2016, LabCorp acquired Sequenom, which helped LabCorp's geographic reach both domestically and internationally, offering services through licensing and commercial partnerships with an emphasis on the European Union and Asia Pacific.
However, inadequate reimbursement policies and stringent regulation is the major factor hindering the market growth. For instance, in 2017, the European government adopted two new regulations on in-vitro diagnostic medical devices for maintaining safety and health of European citizens, for free and fair trade of products throughout the Europe.
The global in-vitro diagnostics market is expected to exhibit a CAGR of 4.6% during the forecast period (2018?2026), owing to rising prevalence of cancer and autoimmune diseases, extensive merger and acquisition activities, and rising trend of point-of-care testing by key players. According to the National Cancer Institute 2017, cancer is among the leading causes of morbidity and mortality globally with over 14 million new registered cases and 8.2 million cancer-related deaths worldwide.
Key players in the market are focused on investment strategies to enhance their research and development activities, which in turn is expected to propel the market growth over the forecast period. For instance, in 2017, Siemens Healthineers commenced a major expansion of its R&D laboratory diagnostics division at Massachusetts, U.S. by investing around US$ 300 million to strengthen its advanced manufacturing sector.
Key players operating in the global in-vitro diagnostics market include Siemens Healthineers, Sysmex Corporation, Bio-Rad Laboratories, bioMérieux S.A., Becton Dickinson, and Company, Danaher Corporation, Abbott Laboratories, F. Hoffmann-la Roche Ltd, QIAGEN N.V., Arkray, Inc., Nittobo Medical Co., Ltd., Medical & Biological Laboratories Co., Ltd., Miraca Holdings Inc., and Mizuho Medy Co., Ltd.
To know the latest trends and insights prevalent in this market, click the link below:
Leading research and experience management firm Sogolytics has released an original study examining the telehealth landscape, highlighting its achievements and challenges in providing positive experiences for patients.
"It's critical for providers...
West Physics Consulting, LLC ("West Physics"), the leading national provider of integrated medical and health physics services, announced today that it has completed the purchase of the medical physics service division of Tricord, Inc. ("Tricord"), a...
Amae Health, a trailblazer in delivering patient-centered care for people with severe mental illness, announced today the successful closing of its oversubscribed $15 million Series A funding round. The round was led by Quiet Capital and included...
Roivios, a pioneering clinical-stage medical device company dedicated to transforming kidney health, is thrilled to announce it has been awarded the prestigious Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA) for its...
Burrell College of Osteopathic Medicine (BCOM) attained the highest level of accreditation from the American Osteopathic Association (AOA) Commission on Osteopathic College Accreditation (COCA). Burrell has been awarded the prestigious accreditation...
Radiance Biopharma ("Radiance" or the "Company"), a biopharmaceutical company specializing in the development of novel Antibody Drug Conjugates (ADCs) and Bispecific ADCs (BsADCs) treatments for cancers, today announced that...